Established in 2004 in response to a growing need for pharmacokinetic (PK) analysis and modelling, the Clinical Pharmacology Analytical Core (CPAC) helps investigators by providing detailed information on drug interactions, quantification of drugs and metabolites, and protein binding of small molecules. CPAC services include preliminary determination of drug metabolism and metabolite identification for future use. These capabilities have been enhanced since acquiring the API 5500 Q-Trap instrument (described below). Once validated in the shared resource, chargebacks are calculated by the IUSCC administration. The process of rational drug design is built upon a strong foundation of biology, chemistry, in vivo pharmacology, and PK. Relevant PK and metabolism studies should be conducted in small animal models or in vitro systems before first drug administration in humans. This allows for the iterative process of implementing structural changes in the drug molecule to optimize the activity of the drug and its pharmacological and PK properties prior to moving to the more regulated and expensive clinical phase of drug development. PK plays an important role in the determination of drug action. The drug discovery process should provide a delicate balance between the chemistry, pharmacology, and PK of the drug. To coordinate these efforts, CPAC is now interacting closely with In Vivo Therapeutics (IVTC), Chemical Genomics, Center for Computational Biology and Bioinformatics, and other IUSCC shared resources. Over the past few years, CPAC and IVTC have worked together to generate data that help Pls better evaluate molecules developed within the IUSCC that show promise as novel cancer drugs. IVTC performs the live phase study {in vivo) and collects samples for CPAC to perform the kinetics. Both core leaders are directly involved in study design prior to project initiation. PK and metabolism data provide important information to guide drug design and treatment in pre-clinical drug discovery (bench) as well as in clinical drug development and treatment (bedside) with efforts focused on evaluation of toxicity and efficacy of new drug candidates. CPAC's state-of-the-art technology and expertise supports research and development of safe and more efficacious drug treatment for IUSCC investigators

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA082709-15
Application #
8781096
Study Section
Subcommittee G - Education (NCI)
Project Start
1999-09-22
Project End
2019-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
15
Fiscal Year
2014
Total Cost
$62,520
Indirect Cost
$25,566
Name
Indiana University-Purdue University at Indianapolis
Department
Type
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Broxmeyer, Hal E; Pelus, Louis M (2014) Inhibition of DPP4/CD26 and dmPGE? treatment enhances engraftment of mouse bone marrow hematopoietic stem cells. Blood Cells Mol Dis 53:34-8
Blue, Emily K; DiGiuseppe, Robert; Derr-Yellin, Ethel et al. (2014) Gestational diabetes induces alterations in the function of neonatal endothelial colony-forming cells. Pediatr Res 75:266-72
Miller, Kathy D; Althouse, Sandra K; Nabell, Lisle et al. (2014) A phase II study of medroxyprogesterone acetate in patients with hormone receptor negative metastatic breast cancer: translational breast cancer research consortium trial 007. Breast Cancer Res Treat 148:99-106
Chiorean, E Gabriela; Schneider, Bryan P; Akisik, Fatih M et al. (2014) Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 89:284-91
Nudelman, Kelly N H; Wang, Yang; McDonald, Brenna C et al. (2014) Altered cerebral blood flow one month after systemic chemotherapy for breast cancer: a prospective study using pulsed arterial spin labeling MRI perfusion. PLoS One 9:e96713
Hocevar, Barbara A; Kamendulis, Lisa M; Pu, Xinzhu et al. (2014) Contribution of environment and genetics to pancreatic cancer susceptibility. PLoS One 9:e90052
Chitteti, Brahmananda Reddy; Kobayashi, Michihiro; Cheng, Yinghua et al. (2014) CD166 regulates human and murine hematopoietic stem cells and the hematopoietic niche. Blood 124:519-29
Chitteti, Brahmananda Reddy; Srour, Edward F (2014) Cell cycle measurement of mouse hematopoietic stem/progenitor cells. Methods Mol Biol 1185:65-78
Chang, Hua-Chen; Lewis, David; Tung, Chun-Yu et al. (2014) Soypeptide lunasin in cytokine immunotherapy for lymphoma. Cancer Immunol Immunother 63:283-95
Speth, Jennifer M; Hoggatt, Jonathan; Singh, Pratibha et al. (2014) Pharmacologic increase in HIF1* enhances hematopoietic stem and progenitor homing and engraftment. Blood 123:203-7

Showing the most recent 10 out of 83 publications